Decinova Therapeutics
Advancing Cell Therapies. Translating Science Into Clinical Possibility.
Decinova Therapeutics is a cell therapy and regenerative medicine company combining proprietary therapeutic development with deep translational expertise.
Our lead platform, Decidua-derived Stromal Cells (DSC), has progressed from fundamental biology through preclinical, manufacturing, regulatory and clinical development — creating a foundation not only for our own therapeutic programs, but also for helping partners advance theirs.
Illustrative visualization of an interconnected stromal-cell network — not a laboratory image.
Three Ways We Create Value
From Proprietary Therapeutics to Partner-Driven Development
DSC — Our Flagship Cell Therapy Platform
Decinova is advancing Decidua-derived Stromal Cells as a differentiated allogeneic stromal-cell platform with extensive translational and clinical-development experience.
Our lead development focus is steroid-refractory acute graft-versus-host disease, a severe and potentially life-threatening complication of allogeneic hematopoietic stem-cell transplantation.
Explore the DSC Platform →Experience Built Through Translation
Developing a cell therapy requires more than promising biology. Decinova supports biotechnology companies, academic groups, hospitals, research institutes and investors in translating cell-based concepts into structured development programs.
Our capabilities span platform assessment, preclinical strategy, process and manufacturing development, characterization and potency strategy, regulatory development, clinical-development planning and technology transfer.
Develop Your Cell Therapy →Cell Technologies Built Around Your Needs
Decinova develops and transfers cell and regenerative-medicine technologies according to partner requirements — including bone-marrow stromal cells, adipose-derived stromal cells, Wharton’s Jelly stromal cells, placental and cord-derived stromal-cell technologies, extracellular vesicles and exosome-related platforms, and custom cell-based technologies.
Explore Technology Development →DSC Flagship Section
From Decidual Biology to a Clinical-Stage Development Platform
DSC originated from research into the unique immunological environment of the human decidua — a tissue naturally adapted to regulate complex immune interactions at the maternal–fetal interface.
That biology led to the development of a distinct stromal-cell platform with potent immunomodulatory properties and characteristics that differentiate DSC from conventional stromal-cell sources.
Over more than 15 years, the platform has accumulated experience across:
- Cell biology and mechanism
- Process development and manufacturing
- Cryopreservation and product handling
- Preclinical and toxicology development
- Clinical administration
- Regulatory development
- Published clinical research
This translational history now provides the foundation for the next stage of DSC development.
Proof Points
A Platform Built Through Translational Experience
DEVELOPMENT
*Claims and regulatory milestones should be presented with appropriate source references and jurisdiction/date context. Historical regulatory designations or authorizations must not be represented as current global approvals.
Lead Development Opportunity: Steroid-Refractory Acute GVHD
Acute graft-versus-host disease remains a major cause of morbidity and mortality following allogeneic hematopoietic stem-cell transplantation. Patients who fail corticosteroid treatment represent a particularly difficult population with substantial unmet medical need.
DSC has generated published clinical experience in severe acute GVHD and provides the foundation for continued clinical development of the platform.
Decinova’s objective is to advance the program through its next clinical-development stage and establish the evidence required for broader regulatory and commercial development.
Why Decinova
We Have Lived the Development Pathway
Cell-therapy development is rarely linear. Biology, manufacturing, potency, preclinical evidence, clinical strategy and regulatory requirements must evolve together.
Decinova’s capabilities were built through the real-world development of DSC — from cell source and biological characterization to manufacturing, preclinical evaluation, clinical administration and regulatory development.
We apply that experience both to our proprietary programs and to selected partner technologies.
Partnership
Different Technologies. Different Starting Points. One Translational Objective.
Decinova works with biotechnology companies, investors, academic institutions, hospitals and research organizations seeking to advance cell and regenerative-medicine technologies.
Opportunities include:
- DSC licensing and co-development
- Strategic investment
- Cell-therapy development programs
- Custom technology development
- Technology transfer
- Manufacturing collaboration
- Scientific and translational collaboration
Let’s Move Cell Therapy Forward.
Whether you’re exploring DSC, developing your own program, or seeking a technology transfer partner — we’d like to hear from you.